Search PubMed⌕ Search

Biomedical subjects

D N Krause

Publications and source records attributed to D N Krause.

At least 37 records · Page 2Linked to original sources

Melatonin directly constricts rat cerebral arteries through modulation of potassium channels.

The pineal hormone melatonin was found to decrease luminal diameter of rat middle cerebral artery segments, pressurized in vitro, in a concentration-dependent manner (concentration that produced a half-maximal effect = 2.7 nM). Contractile responses to melatonin were inhibited by luzindole, a melatonin receptor antagonist, but not by the serotonin receptor antagonist ketanserin. Pertussis toxin abolished the effect of melatonin, which is consistent with involvement of Gi or G(o) protein-coupled receptors. The maximal effect of melatonin was increased by elevating transmural pressure. When compared at the same pressure, contractions elicited by melatonin were smaller than those elicited by serotonin but similar in magnitude to those produced by tetraethylammonium or charybdotoxin, blockers of Ca(2+)-dependent, large-conductance K+ (BKCa) channels. The effect of melatonin was significantly attenuated in the presence of BKCa channel blockers, but not by apamin, a blocker of Ca(2+)-dependent, small-conductance K+ channels. Melatonin, like tetraethylammonium, significantly reduced vasodilation produced by NS-1619, an opener of BKCa channels. Contractile responses to melatonin were diminished in the presence of elevated extracellular K+ (16 mM), but they were not significantly affected by NG-nitro-L-arginine methyl ester. The results suggest that activation of melatonin receptors on rat cerebral arteries increases vascular tone through Gi or G(o) protein-mediated inhibition of BKCa channels. Thus melatonin, which is secreted during the night, can directly influence the contractile state of cerebral arteries.

Animals↗

Sex differences in the effects of 17 beta-estradiol on vascular adrenergic responses.

The in vitro effects of 17 beta-estradiol on vascular responses to adrenergic nerve stimulation were studied in perfused tail arteries from age-matched male and female rats. Nerve stimulation resulted in vasoconstriction that was greater in male arteries. Addition of 17 beta-estradiol (3 x 10(-5) M) reduced the vasoconstrictor responses in both male and female arteries, but the reduction was significantly greater in the females. Gonadectomy of the animals for 1 month prior to the experiment did not alter the in vitro responses to 17 beta-estradiol in either males or females. 17 beta-Estradiol (10(-6) - 3 x 10(-5) M) also relaxed perfused tail arteries precontracted with KCl (50 mM); however the relaxation was not different between males and females, either intact or gonadectomized. Stimulation-evoked release of noradrenaline from adrenergic nerves of perfused tail arteries was measured, but no differences were found between males and females, nor was release modified by in vitro exposure to 17 beta-estradiol (10(-5) M). These results suggest that 17 beta-estradiol acts directly on postjunctional mechanisms to relax tail arteries of either sex. The effect of the hormone on arteries constricted by adrenergic nerve stimulation, however, is greater in females compared to males.

Animals↗

Relaxant effects of 17 beta-estradiol in the rat tail artery are greater in females than males.

To investigate whether sex differences contribute to the variability reported for acute effects of 17 beta-estradiol on vascular reactivity, the response to 17 beta-estradiol was compared in male and female isolated perfused rat tail arteries. 17 beta-Estradiol (10(-7)-10(-5) M) attenuated the contractile response to norepinephrine in female, but not male, arteries, but had no effect when the endothelium was removed. Relaxation to 17 beta-estradiol reached a steady state within approximately 15 min. This hormone appears to acutely relax pre-contracted arteries from females but not males by a non-genomic effect requiring an intact endothelium.

Animals↗

Effects of gonadal steroids on vascular function.

Estrogen and other sex steroid hormones can affect multiple functions of the vascular wall including production and activity of endothelium-derived factors, expression of adhesion molecules, contraction of the smooth muscle to adrenergic nerve stimulation and smooth muscle proliferation and migration. Effects on response of the smooth muscle may be associated with regulation of surface receptors, second messenger systems and contractile protein isoforms. Sex steroid hormones may act synergistically with other hormones to modulate vascular reactivity across the normal ovarian cycle and during pregnancy. Estrogen may also affect remodeling of the vascular wall through inhibition of smooth muscle cell proliferation, stimulation of cell migration and secretion of matrix proteins. It is becoming apparent that modulation of vascular function by sex steroid hormones involves complex interactions. Not all actions of estrogen can be explained by genomic regulation of protein synthesis. Continued progress in understanding how hormones modulate vascular function will depend, in part, on clearer interpretation of data relative to the particular conditions of each experiment. Important aspects to be considered include the effect of gender and vessel type on the distribution and function of hormone receptors present in the vessel wall; use of hormones within physiological concentration ranges; and more precise determination of the influence of hormone treatment duration whether acute, subacute or chronic.

Animals↗

Melatonin receptors mediate potentiation of contractile responses to adrenergic nerve stimulation in rat caudal artery.

The hormone melatonin potentiated contractile responses to adrenergic nerve stimulation in isolated ring segments of rat caudal artery. This effect was inhibited by the melatonin receptor antagonist luzindole but not by the serotonin 5-HT2 receptor antagonist ketanserin. Melatonin had no direct effects on vascular tone. Melatonin agonists potentiated contractile responses with a relative order of potency (2-iodomelatonin, EC50 = 0.6 nM; melatonin, EC50 = 4.7 nM; N-acetylserotonin, EC50 = 1.5 microM) that is consistent with the melatonin ML1 receptor subtype. Melatonin also potentiated contractions elicited by exogenous norepinephrine and produced its effects in the absence of an intact endothelium. These data suggest that melatonin acts on receptors in the smooth muscle. The caudal artery provides a useful functional assay for pharmacological analysis of melatonin receptors. Physiologically, melatonin may activate its receptors at night to influence thermoregulation in the rat by enhancing the effects of sympathetic input to the caudal artery.

Animals↗

Unilateral optic nerve transection decreases 2-[125I]-iodomelatonin binding in retinorecipient areas and visual pathways of chick brain.

In chick brain, specific 2-[125I]-iodomelatonin-binding was localized primarily in the visual system, i.e., retinorecipient and relay nuclei and fiber tracts of the tectofugal, thalamofugal, circadian and accessory visual pathways. Unilateral transection of the optic nerve (ONX) significantly reduced the binding of 2-[125I]-iodomelatonin (75 pM) in many, but not all, primary retinal targets and visual pathways at 7 and 14 days, but not 1 day, postlesion. As measured using quantitative autoradiography, 2-[125I]-iodomelatonin binding was decreased by 90% in both the central portion of the lesioned optic tract and one of its targets, the nucleus of the basal optic root (nBOR). Other retinorecipient areas exhibiting substantial decreases (60%) in 2-[125I]-iodomelatonin-binding included the optic tectum, lateroventral and dorsolateral geniculate nuclei and tectal gray area contralateral to the lesion. These findings are consistent with the hypothesis that melatonin receptors are located presynaptically on incoming optic nerve terminals in many retinorecipient areas. This localization may account for most of the binding sites in nBOR. In other primary visual areas, however, melatonin receptors also appear to be located on postsynaptic cells and/or non-retinal afferents. ONX had no significant effect on 2-[125I] -iodomelatonin binding in two retinorecipient areas, the visual suprachiasmatic nucleus and the dorsolateral anterior thalamus, which are part of the circadian/oculomotor and thalamofugal pathways, respectively. An unexpected consequence of ONX was that 2-[125I]- iodomelatonin binding was decreased in certain secondary (nucleus rotundus, isthmi nuclei) and tertiary level (ectostriatum) nuclei along the prominent tectofugal visual pathway. Binding in the tectorecipient nucleus triangularis was not significantly altered, however. Analysis of secondary level relay nuclei in the oculomotor pathway revealed that binding after ONX was decreased in the ipsilateral Edinger-Westphal nucleus but not in the oculomotor nuclei. Selective transsynaptic changes in 2-[125I]-iodomelatonin binding after lesion of the visual input most likely reflect activity-dependent regulation and functional plasticity of central melatonin receptors.

Animals↗

Optic nerve transection decreases 2-[125I]iodomelatonin binding in the chick optic tectum.

The distribution of specific 2-[125I]iodomelatonin binding sites in the various layers of the chick optic tectum was analyzed using quantitative receptor autoradiography. Following unilateral optic nerve transection, binding in the optic fiber layer and superficial retinorecipient layers of the contralateral tectum was significantly decreased at 7 and 14 days, but not at 1 day, following transection. The results are consistent with the presence of presynaptic melatonin receptors on axon terminals of retinotectal fibers.

Animals↗

Complex prejunctional actions of the D2 dopamine agonists N-0923 and N-0924 in the rat tail artery.

In rat tail arteries preloaded with [3H]norepinephrine, the D2 dopamine receptor agonist N-0923 [(S)-(-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin++ +], (S)-(-)-enantiomer of N-0437 [2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin], inhibited tritium efflux and contractile responses evoked by nerve stimulation, indicating a prejunctional site of action. At higher concentrations (greater than or equal to 10(-7) M), N-0923 had additional effects which were blocked by the alpha-2 receptor antagonist yohimbine. In the presence of yohimbine, inhibition by N-0923 (10(-9) to 10(-6) M) of stimulation-evoked contractile responses correlated well with inhibition of tritium efflux, effects which were antagonized by sulpiride. The (R)-(+) enantiomer, N-0924 [(R)-(+)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin++ +], also inhibited stimulation-evoked contractile responses (EC50 = 5.0 x 10(-7) M) and tritium efflux (EC50 = 6.0 x 10(-7) M) in the presence of yohimbine, but with reduced potency compared to N-0923 (EC50 = 4.0 x 10(-9) and 4.2 x 10(-9) M, respectively). At high concentrations (10(-6) M), both enantiomers also increased basal tritium efflux, an effect which coincided with contraction in the case of N-0923. The effect of N-0923 at the D2 receptor, measured as inhibition of stimulation-evoked contractile responses, was greatest when the intensity of stimulation was low (low frequency or short train lengths). When extracellular calcium was lowered to 1.0 mM, the inhibitory effect of N-0923 was increased whereas elevated calcium (5.0 mM) attenuated the action of N-0923.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗

The area of 2-[125I] iodomelatonin binding in the pars tuberalis of the ground squirrel is decreased during hibernation.

Quantitative receptor autoradiography was used to analyze 2-[125I]iodomelatonin binding sites in the brains of golden-mantled ground squirrels (Citellus lateralis). Specific binding appeared to be discretely localized to the pars tuberalis region of the pituitary that surrounds the medial basal hypothalamus. The total area of binding was significantly decreased in brains of hibernating squirrels as compared to those of awake, euthermic animals. These findings support a role for melatonin receptors of the pars tuberalis in seasonal behavior.

Animals↗

Heterogeneity of muscarinic receptor subtypes in cerebral blood vessels.

The identity and distribution of muscarinic cholinergic receptor subtypes and associated signal transduction mechanisms was characterized for the cerebral circulation using correlated functional and biochemical investigations. Subtypes were distinguished by the relative affinities of a panel of muscarinic antagonists, pirenzepine, AF-DX 116 [11-2-[[2-[diethylaminomethyl]- 1-piperidinyl]acetyl]-5,11-dihydro-6H- pyrido[2,3-b][1,4]benzodiazepine-6-one], hexahydrosiladifenidol, methoctramine, 4-diphenylacetoxy-N-methylpiperidine methobromide, dicyclomine, para-fluoro-hexahydrosiladifenidol and atropine. Muscarinic receptors characterized by inhibition of [3H]quinuclidinylbenzilate binding in membranes of bovine pial arteries were of the M2 subtype. In contrast pharmacological analysis of [3H]-quinuclidinylbenzilate binding in bovine intracerebral microvessels suggests the presence of an M4 subtype. Receptors mediating endothelium-dependent vasodilation in rabbit pial arteries were of the M3 subtype, whereas muscarinic receptors stimulating endothelium-independent phosphoinositide hydrolysis in bovine pial arteries were of the M1 subtype. These findings suggest that characteristics of muscarinic receptors in cerebral blood vessels vary depending on the type of vessel, cellular location and function mediated.

Animals↗

Quantitative pharmacological analysis of 2-125I-iodomelatonin binding sites in discrete areas of the chicken brain.

We have localized and characterized 2-125I-iodomelatonin binding sites in the chicken brain using in vitro quantitative autoradiography. Binding sites were widely distributed throughout the chicken brain, predominantly in regions associated with the visual system. The specific binding of 2-125I-iodomelatonin to discrete chicken brain areas was found to be saturable, reversible, and of high affinity. The specific binding of 2-125I-iodomelatonin (75 pm) was quantitated for 40 identifiable brain regions. Eight brain regions were chosen for binding characterization and pharmacological analysis: optic tectum, Edinger-Westphal nucleus, oculomotor nucleus, nucleus rotundus, ventral supraoptic decussation, ventrolateral geniculate nucleus, neostriatum, and ectostriatum. These regions showed no rostral-caudal gradient in 2-125I-iodomelatonin specific binding, and saturation analysis revealed a single class of high-affinity sites with KD values in the range of 33-48 pM and receptor site density (Bmax) ranging from 31 to 58 fmol/mg protein. Competition experiments carried out with various indoles revealed a similar order of pharmacological affinities in these areas: melatonin greater than 6-chloromelatonin greater than methoxyluzindole greater than N-acetylserotonin greater than luzindole much greater than 5-HT greater than 5-methoxytryptamine. The affinity constants determined by quantitative autoradiography for these compounds to compete for 2-125I-iodomelatonin binding in the optic tectum correlated well with the affinities in chicken brain membranes at 25 degrees C (r = 0.966; slope = 0.845; n = 7) and 0 degree C (r = 0.946; slope = 0.379; n = 7), chicken retinal membranes (r = 0.973; slope = 0.759; n = 7), and the potency or affinity of these compounds to affect the calcium-dependent release of 3H-dopamine from the rabbit retina (r = 0.902; slope = 0.506; n = 6). We conclude that the high-affinity sites labeled by 2-125I-iodomelatonin in various chicken brain areas have identical binding and pharmacological characteristics to the ML-1 melatonin binding site previously described in chicken brain and retinal membranes and to the ML-1 melatonin receptor modulating dopamine release from the retina. In the chicken brain, the ML-1 receptor site may mediate functional responses regulated by melatonin.

Animals↗

Muscarinic M1 receptors stimulate phosphoinositide hydrolysis in bovine cerebral arteries.

The muscarinic agonist oxotremorine-M produced a concentration-dependent increase in phosphoinositide hydrolysis in bovine pial arteries. The maximal effect was 5.9 +/- 0.89 fold over basal levels, and the EC50 for oxotremorine-M was 8.9 x 10(-6) M. The phosphoinositide response in arteries with the luminal endothelium removed was similar to the response in intact arteries. The specific muscarinic antagonists pirenzepine, 4-DAMP and methoctramine produced parallel shifts of the concentration-response curve to oxotremorine-M, with the following order of potency (pKB): 4-DAMP (8.59 +/- 0.10) greater than pirenzepine (8.12 +/- 0.11) greater than methoctramine (6.77 +/- 0.20). These results indicate that muscarinic stimulation activates phosphoinositide hydrolysis in cerebral arteries, and that the muscarinic receptors mediating this increase are similar to the M1 subtype.

Animals↗

Regulatory sites in the melatonin system of mammals.

The hormone melatonin was first identified about 30 years ago as a secretory product of the pineal gland. In mammals, the daily rhythm of pineal melatonin synthesis is controlled by neural inputs. The CNS is thought to be a primary target organ involved in mediating the influence of melatonin on a variety of physiological and behavioral processes, including biological rhythms, neuroendocrine function, activity levels and sleep. It now appears that melatonin is also produced in the retina and affects various aspects of retinal physiology. The purpose of this article is to provide a brief overview of potential regulatory sites involved in the production and action of melatonin. In particular, this review focuses on the rapid advances being made in the characterization and localization of melatonin receptors in the CNS, retina and pituitary and on recent findings pertaining to the regulation of melatonin synthesis in the mammalian pineal gland and retina.

Animals↗

Prejunctional inhibitory effect of a dopamine D-2 agonist, N-0437, on vascular adrenergic responses.

N-0437 [2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin], a potent and selective agonist for D-2 dopamine receptors, was used to investigate inhibitory prejunctional dopamine receptors in the rat tail artery and rabbit ear artery. N-0437 inhibited contractile responses to transmural nerve stimulation in a frequency dependent manner. Thus, N-0437 profoundly inhibited responses to nerve stimulation in the rat tail artery at a frequency of 1 Hz (ED50 = 1.6 nM), but had minimal effects when nerves were stimulated at 6 Hz. The D-1/D-2 dopamine agonist, apomorphine, exhibited a similar frequency dependent inhibitory effect but with less potency (ED50 = 30 nM at 1 Hz). In concentrations up to 1 microM, N-0437 had no effect on responses to exogenously applied norepinephrine, but N-0437 inhibited [3H] norepinephrine efflux induced by transmural stimulation. Inhibitory effects of N-0437 were blocked by the D-2 antagonist sulpiride but not by the D-1 antagonist SCH 23390. Furthermore, the selective D-1 agonist SKF 38393 did not inhibit vascular responses to adrenergic nerve stimulation. These data indicate that the inhibitory effects of N-0437 are via activation of D-2 dopamine receptors that inhibit norepinephrine release. Thus, N-0437 shows potency and selectivity of action for prejunctional D-2 dopamine receptors in vascular tissues. The frequency dependence of the actions of N-0437 suggest that the level of sympathetic activity is an important variable in determining effectiveness of prejunctional modulation.

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-ben↗

N-0437: a selective D-2 dopamine receptor agonist in in vitro and in vivo models.

The selectivity of the potent dopamine D-2 agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin (N-0437) was examined in a series of in vivo and in vitro pharmacological models. In radioligand binding assays, N-0437 showed high potency (Ki = 0.69 nM) and selectivity for D-2 receptors as compared to its potency and selectivity at various other neuronal receptors (Ki in nM): D-1 (678) dopamine, alpha 1-(534) and alpha 2-(195) adrenoceptor, S1-(6940) and S2-(5900) serotonin and muscarine (2660). Very low activity (Ki greater than 10(-5) M) was seen at the beta-adrenoceptor, A1-adenosine, GABAA and benzodiazepine receptors. Furthermore, N-0437 inhibited the calcium-dependent release of [3H]dopamine (IC50: 4 nM) and [3H]acetylcholine (IC50: 6.3 nM) from rabbit striatal slices in the nanomolar range. These effects of N-0437 were mediated through activation of D-2 dopamine autoreceptors and D-2 dopamine heteroreceptors, respectively. Presynaptic dopaminergic activity in vivo was measurable as an inhibition of the locomotor activity of mice, and in this model N-0437 was more effective than apomorphine. Moreover, the effect of N-0437 could be antagonized by sulpiride but not by yohimbine. N-0437 was equipotent with apomorphine in inducing circling behaviour in 6-OHDA-lesioned rats. N-0437 had almost no serotonergic activity in vivo. The results show that N-0437 is a selective dopamine D-2 agonist, and thus, that it is a new ligand of choice for studies on the D-2 receptor.

Acetylcholine↗